Literature DB >> 21332971

Infection, vascularization, remodelling--are stem cells the answers for bone diseases of the jaws?

Jörg Handschel, Ulrich Meyer.   

Abstract

Osteonecrosis after craniofacial radiation (ORN), osteomyelitis and bisphosphonates related necrosis of the jaw (BRONJ) are the predominant bone diseases in Cranio- and Maxillofacial surgery. Although various hypothesis for the pathophysiological mechanisms including infection, altered vascularisation or remodelling exist, the treatment is still a challenge for clinicians. As the classical pharmacological or surgical treatment protocols have only limited success, stem cells might be a promising treatment option, indicated by recently published data.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21332971      PMCID: PMC3055822          DOI: 10.1186/1746-160X-7-5

Source DB:  PubMed          Journal:  Head Face Med        ISSN: 1746-160X            Impact factor:   2.151


In maxillofacial surgery clinicians face three diseases of the jaws predominantly: osteonecrosis after craniofacial radiation (ORN), osteomyelitis and bisphosphonates related necrosis of the jaw (BRONJ). Numerous reports exist suggesting various pathological mechanisms and treatment modalities for these diseases [1,2]. Although these publications elucidate the prevalence, risk factors and treatment strategies, they have provided limited data on details of the underlying pathophysiology, especially differences in the three above mentioned diseases. The local or total immunsupressive therapy of many patients (e.g. cancer patients) and the universal presence of hundreds of microorganisms in the oral cavity provide a perfect environment for chronic infections like osteomyelitis. It is unclear if this contributes to BROMJ too. Currently, most evidence exist that the necrotic tissue becomes infected as opposed to the infected tissue becomes necrotic [3]. Regarding the effects on the immune system inconsistent data are reported in the literature. On the one hand bisphosphonates inhibit T lymphocyte activation and proliferation and suppress monocytes production of various pro-inflammatory cytokines [4]. On the other hand they increase the production of pro-inflammatory cytokines by lymphocytes [5]. Whereas the most widely accepted theory to explain the cause of ORN is the theory of hypoxia, radio-induced hypovascularity and hypocellularity [6,7] there is no evidence that the necrotic regions in BRONJ have reduced vasculature or blood supply. However, antiangiogenic effects of bisphosphonates have been reported by other authors [8]. Remoddeling suppression is an other causative factor held responsible for BRONJ despite the fact that there are no published data in humans showing the effects of bisphosphonates on jaw remodeling [2]. Taken together there are only very few studies (e.g. animal studies) clarifying the basic pathophysiological mechanisms of these bone diseases. Very recently, a new treatment modality was introduced elucidating one possible causative factor for BRONJ. Kikuiri and coworkers infused mesenchymal stem cells in BRONJ-like mice. The stem cells modulated the immune system, prevent and cure BRONJ-like disease [9]. Since it is known, that stem cells can induce ectopic bone formation [10] as well as angiogenesis [11], stem cells might be a future treatment option for the above mentioned bone diseases. Particularly, with respect to the full capacity of various stem cell lines [12,13], these cells might become a promising tool for clinicians.
  12 in total

1.  Long-term alterations of oral mucosa in radiotherapy patients.

Authors:  Franz-Josef Prott; Jörg Handschel; Oliver Micke; Cord Sunderkötter; Ulrich Meyer; Josef Piffko
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

Review 2.  Osteoradionecrosis of the jaws--a current overview--part 1: Physiopathology and risk and predisposing factors.

Authors:  Bruno Ramos Chrcanovic; Peter Reher; Alexandre Andrade Sousa; Malcolm Harris
Journal:  Oral Maxillofac Surg       Date:  2010-03

3.  Comparison of ectopic bone formation of embryonic stem cells and cord blood stem cells in vivo.

Authors:  Jörg Handschel; Christian Naujoks; Fabian Langenbach; Karin Berr; Rita A Depprich; Michelle A Ommerborn; Norbert R Kübler; Matthias Brinkmann; Gesine Kögler; Ulrich Meyer
Journal:  Tissue Eng Part A       Date:  2010-08       Impact factor: 3.845

Review 4.  Recent advances in understanding the mechanism of action of bisphosphonates.

Authors:  Fraser P Coxon; Keith Thompson; Michael J Rogers
Journal:  Curr Opin Pharmacol       Date:  2006-05-02       Impact factor: 5.547

5.  Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.

Authors:  N Yarom; R Yahalom; Y Shoshani; W Hamed; E Regev; S Elad
Journal:  Osteoporos Int       Date:  2007-06-28       Impact factor: 4.507

Review 6.  The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.

Authors:  Matthew R Allen; David B Burr
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

7.  Inhibition of antigen-presenting cell function by alendronate in vitro.

Authors:  P Sansoni; G Passeri; F Fagnoni; N Mohagheghpour; G Snelli; V Brianti; E G Engleman
Journal:  J Bone Miner Res       Date:  1995-11       Impact factor: 6.741

8.  Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

Authors:  Jeanette Wood; Karine Bonjean; Stephan Ruetz; Akeila Bellahcène; Laetitia Devy; Jean Michel Foidart; Vincent Castronovo; Jonathan R Green
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

9.  Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.

Authors:  Takashi Kikuiri; Insoo Kim; Takyoshi Yamaza; Kentaro Akiyama; Qunzhou Zhang; Yunsheng Li; Chider Chen; WanJun Chen; Songlin Wang; Anh D Le; Songtao Shi
Journal:  J Bone Miner Res       Date:  2010-07       Impact factor: 6.741

10.  Induction of osteogenic markers in differentially treated cultures of embryonic stem cells.

Authors:  Jörg Handschel; Karin Berr; Rita A Depprich; Norbert R Kübler; Christian Naujoks; Hans-Peter Wiesmann; Michelle A Ommerborn; Ulrich Meyer
Journal:  Head Face Med       Date:  2008-06-10       Impact factor: 2.151

View more
  4 in total

1.  Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.

Authors:  Pit Jacob Voss; Akihiko Matsumoto; Esteban Alvarado; Rainer Schmelzeisen; Fabian Duttenhöfer; Philipp Poxleitner
Journal:  Odontology       Date:  2017-02-20       Impact factor: 2.634

2.  Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw.

Authors:  Luigi Cella; Aldo Oppici; Mariacristina Arbasi; Mauro Moretto; Massimo Piepoli; Daniele Vallisa; Adriano Zangrandi; Camilla Di Nunzio; Luigi Cavanna
Journal:  Head Face Med       Date:  2011-08-17       Impact factor: 2.151

3.  Cell therapy stimulates bone neoformation in calvaria defects in rats subjected to local irradiation.

Authors:  Ana Luisa Riul Sório; Paula Katherine Vargas-Sanchez; Roger Rodrigo Fernandes; Dimitrius Leonardo Pitol; Luiz Gustavo de Sousa; Adriano Luiz Balthazar Bianchini; Geraldo Batista de Melo; Selma Siessere; Karina Fittipaldi Bombonato-Prado
Journal:  Animal Model Exp Med       Date:  2019-07-01

4.  Adipose-Derived Stromal Cells Are Capable of Restoring Bone Regeneration After Post-Traumatic Osteomyelitis and Modulate B-Cell Response.

Authors:  Johannes Maximilian Wagner; Felix Reinkemeier; Christoph Wallner; Mehran Dadras; Julika Huber; Sonja Verena Schmidt; Marius Drysch; Stephanie Dittfeld; Henriette Jaurich; Mustafa Becerikli; Kathrin Becker; Nicole Rauch; Vikas Duhan; Marcus Lehnhardt; Björn Behr
Journal:  Stem Cells Transl Med       Date:  2019-06-10       Impact factor: 6.940

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.